The drugs price regulator National Pharmaceutical Pricing Authority (NPPA) on 11 May 2016 fixed the ceiling price of 54 drug formulations used for treatment of cancer, diabetes rheumatoid arthritis, bacterial infections and hypertension.
The ceiling prices were revised/fixed by NPPA as per the Schedule-I under Drugs (Price Control) Amendment Order (DPCO), 2016.
Apart from this, it also fixed the retail price of 11 formulations under DPCO, 2013, which covers 680 formulations.
DPCO, 2013 was notified on 15 May 2013 replacing the 1995 order that regulated prices of only 74 bulk drugs.
It has also fixed the retail price of the following formulations like glimepiride + metformin HCl tablet (walaphage G1 forte), amoxycillin trihydrate + potassium clavulanate syrup (ampilox CV 457) and teneligliptin + metformin HCl ER tablet.
The drug pricing regulator had 15 days back fixed ceiling prices of 54 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 on the basis of Wholesale Price Index (WPI) and retail price of 2 formulations.